Regeneron Pharmaceuticals (REGN) Other Non-Current Assets (2009 - 2026)

Regeneron Pharmaceuticals' Other Non-Current Assets history runs 18 years deep, the most recent figure standing at $2.1 billion for Q1 2026.

• On a quarterly basis, Other Non-Current Assets rose 52.87% year-over-year to $2.1 billion in Q1 2026; TTM through Mar 2026 was $2.1 billion, a 52.87% increase from a year earlier, with the FY2025 full-year figure at $1.8 billion, up 60.32% from the prior year.
• Other Non-Current Assets improved to $2.1 billion in Q1 2026 per REGN's latest filing, from $1.8 billion in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $2.1 billion in Q1 2026 and bottomed at $262.0 million in Q1 2022.
• The 5-year median for Other Non-Current Assets is $470.2 million (2024), against an average of $881.3 million.
• Across the five-year window, Other Non-Current Assets advanced 28.01% in 2023 and soared 196.28% in 2025, its largest moves.
• Year by year, Other Non-Current Assets stood at $336.4 million in 2022, then soared by 32.02% to $444.1 million in 2023, then soared by 155.8% to $1.1 billion in 2024, then surged by 60.32% to $1.8 billion in 2025, then rose by 16.94% to $2.1 billion in 2026.
• Per Business Quant, the three latest REGN Other Non-Current Assets figures stand at $2.1 billion (Q1 2026), $1.8 billion (Q4 2025), and $1.7 billion (Q3 2025).